Xspray Pharma provides an update on its second product candidate, XS003: New data shows matching bioavailability to Tasigna® at more than a 50% reduced dose. STOCKHOLM--(BUSINESS WIRE)-- Xspray ...

Cipla Secures USFDA Nod for Nilotinib, Set for 2025-26 Launch 20 Feb 2025 , 11:46 PM Cipla has got final approval from the USFDA for New Drug Application (NDA) for its Nilotinib Capsules 50 mg ...

Patients with chronic myeloid leukemia who have attained sustained deep molecular response with second-line nilotinib therapy can achieve treatment-free remission for 48 weeks or longer, according ...

The risk for diabetes, hyperlipidemia, and cardiovascular disease is higher in patients receiving nilotinib (Tasigna) vs other tyrosine kinase inhibitors for chronic myeloid leukemia (CML). To ...

The FDA has approved Danziten™, a nilotinib formulation with no mealtime restrictions, for the treatment of adults with newly diagnosed Ph+ CML-CP and resistant or intolerant Ph+ CML-CP and CML-AP.

WESTON, Fla., May 27, 2025 /PRNewswire/ - Apotex Corp. today announced the launch of nilotinib capsules, a generic version of Tasigna®, in the United States, with 180 days of exclusivity.

Xspray Pharma provides an update on its second product candidate, XS003: New data shows matching bioavailability to Tasigna® at more than a 50% reduced dose. STOCKHOLM, July 09, 2024--(BUSINESS ...

WESTON, Fla., May 27, 2025 /PRNewswire/ - Apotex Corp. today announced the launch of nilotinib capsules, a generic version of Tasigna®, in the United States, with 180 days of exclusivity ...

Xspray Pharma’s XS003 Study Shows Matching Bioavailability to Tasigna at More than a 50% Lower Dose ...

STOCKHOLM, July 09, 2024--Xspray Pharma AB (Stockholm/Nasdaq: XSPRAY), a biotechnology company focused on developing improved protein kinase inhibitors (PKIs) for cancer treatment using its ...